project id: TCGA-PRAD; case submitter id: TCGA-EJ-A65D; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.83; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 2.25; rna integrity number: 9.8; age at index: 66; days to birth: -24297; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1946; age at diagnosis: 24297; ajcc clinical m: M0; ajcc clinical t: T3a; ajcc pathologic n: N0; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 393.0; icd 10 code: C61; last known disease status: not reported; morphology: 8500/3; primary diagnosis: Infiltrating duct carcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 240; initial weight: 270.0; sample id: 243da837-f54b-449c-a7e7-5737935d53d6; sample submitter id: TCGA-EJ-A65D-01A; portion id: f5a3365e-09a9-491d-8095-a7949ea6fbe1; portion submitter id: TCGA-EJ-A65D-01A-11; slide id: 79e9504c-73cc-43c7-baae-ea0b7cdfad7b; slide submitter id: TCGA-EJ-A65D-01A-01-TSA; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 3.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 15.0; percent tumor cells: 85.0; percent tumor nuclei: 95.0; section location: TOP;